Alterations of the cell-cycle inhibitors p27 KIP1 and p16 INK4a are frequent in blastic plasmacytoid dendritic cell neoplasms

Journal of Investigative Dermatology

Volumn 130, Issue 4, 2010, Pages 1152-1157

  Wiesner, Thomas ^a   Obenauf, Anna C ^a   Cota, Carlo ^b   Fried, Isabella ^a   Speicher, Michael R ^a   Cerroni, Lorenzo ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CHROMOSOMAL INSTABILITY; CHROMOSOME 12P; CHROMOSOME 13; CHROMOSOME 15; CHROMOSOME 5Q; CHROMOSOME 9; CHROMOSOME LOSS; CLINICAL ARTICLE; FEMALE; GENE LOCUS; HAPLOTYPE; HUMAN; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; SKIN BIOPSY; TUMOR CELL;

EID: 77949531452     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.369     Document Type: Article

References (14)

1. Ascani S, Massone C, Ferrara G et al. (2008) CD4-negative variant of CD4+/ CD56+ hematodermic neoplasm: description of three cases. J Cutan Pathol 35:911-915
2. Bohlander SK (2005) ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 15:162-174
3. Chu I, Hengst L, Slingerland J (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8:253-267
4. Dijkman R, Van Doorn R, Szuhai K et al. (2007) Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 109:1720-1727
5. Facchetti F, Jones D, Petrella T (2008) Blastic plasmacytoid dendritic cell neoplasms. In: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. (Swerdlow SH, Campo E, Harries NL, Jaffe ES, Pileri SA, Stein H, et al., eds) Lyon: IARC. pp 145-147
6. Fero ML, Randel E, Gurley KE et al. (1998) The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396:177-180
7. Jardin F, Callanan M, Penther D et al. (2009) Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia 23:698-707
8. Kim WY, Sharpless NE (2006) The regulation of INK4/ARF in cancer and aging. Cell 127:265-275
9. Leroux D, Mugneret F, Callanan M et al. (2002) CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique. Blood 99:4154-4159
10. Mao X, Onadim Z, Price EA et al. (2003) Genomic alterations in blastic natural killer/extranodal natural killer-like T cell lymphoma with cutaneous involvement. J Invest Dermatol 121:618-627
11. Meric-Bernstam F, Gonzalez-Angulo A (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27:2278-2287
12. Petrella T, Dalac S, Maynadié M et al. (1999) CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français dEtude des Lymphomes Cutanés (GFELC). Am J Surg Pathol 23:137-146
13. Reichard KK, Burks EJ, Foucar MK et al. (2005) CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 29:1274-1283
14. Sherr C, Roberts JM (2004) Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18:2699-2711